Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
COVID-19 is an infectious disease caused by SARS-CoV2 virus. The objective of our study is to analyze the progression and the severity of COVID-19 in patients with RA. Indeed, few data are available on this subject, and this would allow us to improve management of COVID-19 in these potential at-risk patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Hospitalization rates for COVID-19 | Proportion of hospitalized patients in RA group or control group. From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery. | 1 day |
| Measure | Description | Time Frame |
|---|---|---|
| Critical care transfer rate for COVID-19 and death due to COVID-19 | Proportion of patients transferred in critical care for COVID-19 or deaths due to COVID-19 From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery. | 1 day |
| Pulmonary comorbidities, corticosteroids or DMARDs use |
Not provided
Inclusion criteria:
- Confirmed COVID-19 diagnosis (positive PCR or serology) in RA patients or healthy controls.
Exclusion criteria:
Not provided
Not provided
Not provided
Study population description: *
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Padern Guillaume, physician | University Hospitals of Montpellier | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UH Montpellier | Montpellier | 34295 | France |
NC
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Type and severity of patients pulmonary comorbidities and treatment by corticosteroids or DMARDs in RA group From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery. |
| 1 day |
| Age | Patients demographics From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery. | 1 day |
| Number of Participants with co-morbidities | Patients comorbidities From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery. | 1 day |
| Type of clinical presentation | Patients COVID-19 clinical presentation From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery. | 1 day |
| Type of associated treatments | From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery. | 1 day |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |